HC Wainwright Reiterates Buy Rating for Perspective Therapeutics (NYSE:CATX)

Key Points

• HC Wainwright has reiterated a buy rating for Perspective Therapeutics (NYSE:CATX) with a target price of $10.00, indicating a potential upside of 186.53% from its previous close.
• Other analysts have also expressed positive views, with Wedbush setting a target price of $11.00 and B. Riley increasing theirs to $12.00, contributing to a consensus rating of "Buy" with a target price of $12.56.
• Perspective Therapeutics is focused on developing precision-targeted alpha therapies for oncology, with its initial programs currently in Phase 1/2a clinical trials for various cancer treatments.

Perspective Therapeutics (NYSE:CATX - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright's target price would suggest a potential upside of 186.53% from the company's previous close.

Several other equities research analysts also recently weighed in on the company. Wedbush restated an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Thursday. Lifesci Capital raised Perspective Therapeutics to a "strong-buy" rating in a report on Saturday, July 12th. Finally, B. Riley reiterated a "buy" rating and set a $12.00 target price (up from $9.00) on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $12.56.

Perspective Therapeutics Stock Up 1.7%

Shares of Perspective Therapeutics stock opened at $3.49 on Friday. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $13.56. The business's fifty day simple moving average is $3.54 and its 200-day simple moving average is $3.07.

Institutional Trading of Perspective Therapeutics

Large investors have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC boosted its stake in Perspective Therapeutics by 71.1% during the 1st quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company's stock valued at $4,738,000 after purchasing an additional 924,196 shares in the last quarter. Nicholson Wealth Management Group LLC raised its holdings in shares of Perspective Therapeutics by 0.3% during the second quarter. Nicholson Wealth Management Group LLC now owns 1,614,283 shares of the company's stock worth $5,553,000 after acquiring an additional 5,000 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Perspective Therapeutics by 15.8% during the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company's stock worth $4,758,000 after acquiring an additional 188,887 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Perspective Therapeutics during the first quarter worth $2,647,000. Finally, JPMorgan Chase & Co. raised its holdings in Perspective Therapeutics by 118.4% during the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company's stock valued at $2,573,000 after buying an additional 405,612 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.